Journal
MOLECULAR ORAL MICROBIOLOGY
Volume 36, Issue 6, Pages 291-294Publisher
WILEY
DOI: 10.1111/omi.12351
Keywords
COVID-19; lncRNA; MALAT1; nasopharyngeal samples; NEAT1; saliva; SARS-CoV-2
Categories
Funding
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
- Projetos Individuais no Combate a Covid-19 (Proind 2020)
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
Ask authors/readers for more resources
This study investigated the expression of lncRNAs in saliva and nasopharyngeal samples of COVID-19 patients for the first time, finding higher expression of NEAT1 and MALAT1 in positive samples, providing new insights into the initial response to infection and infectivity.
COVID-19, caused by the SARS-CoV-2 virus, has become a significant global public health problem, with a wide variety of clinical manifestations and disease progression outcomes. LncRNAs are key regulators of the immune response and have been associated with COVID-19 risk infection. Previous studies focused mainly on in-silico analysis of lncRNA expression in the lungs or peripheral blood cells. We evaluated the expression of lncRNAs NEAT1, MALAT1, and MIR3142 in saliva and nasopharyngeal swab from SARS-CoV-2 positive (n = 34) and negative patients (n = 46). A higher expression of the lncRNAs NEAT1 and MALAT1 (p < 0.05) were found in positive samples. NEAT1 had a higher expression mainly in saliva samples (p < 0.001), and MALAT1 was upregulated in nasopharyngeal samples (p < 0.05). Area under the ROC curve for NEAT1 in saliva was 0.8067. This study was the first to investigate the expression of lncRNAs in saliva and nasopharyngeal samples of COVID-19 patients, which gives new insights into the initial response to infection and infectivity and may provide new biomarkers for severity and targets for therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available